These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36809347)

  • 1. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study.
    Fournier A; Cairat M; Severi G; Gunter MJ; Rinaldi S; Dossus L
    J Natl Cancer Inst; 2023 Jun; 115(6):671-679. PubMed ID: 36809347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
    J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort.
    Fournier A; Mesrine S; Dossus L; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
    Breast Cancer Res Treat; 2014 Jun; 145(2):535-43. PubMed ID: 24781971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
    Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
    J Clin Oncol; 2009 Nov; 27(31):5138-43. PubMed ID: 19752341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menopausal hormone therapy and cancer risk: An overestimated risk?
    Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
    Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Simin J; Tamimi RM; Callens S; Engstrand L; Brusselaers N
    Int J Cancer; 2020 Jul; 147(1):33-44. PubMed ID: 31584190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.
    Fournier A; Berrino F; Clavel-Chapelon F
    Breast Cancer Res Treat; 2008 Jan; 107(1):103-11. PubMed ID: 17333341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
    Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
    PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
    Petrick JL; Joslin CE; Johnson CE; Camacho TF; Peres LC; Bandera EV; Barnard ME; Beeghly A; Bethea TN; Dempsey LF; Guertin K; Harris HR; Moorman PG; Myers ER; Ochs-Balcom HM; Rosenow W; Setiawan VW; Wu AH; Schildkraut JM; Rosenberg L
    Br J Cancer; 2023 Dec; 129(12):1956-1967. PubMed ID: 37865688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is breast cancer risk the same for all progestogens?
    Stute P
    Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal hormone therapy and asthma onset in the E3N cohort.
    Romieu I; Fabre A; Fournier A; Kauffmann F; Varraso R; Mesrine S; Leynaert B; Clavel-Chapelon F
    Thorax; 2010 Apr; 65(4):292-7. PubMed ID: 20142267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
    Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
    J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Collaborative Group on Hormonal Factors in Breast Cancer
    Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008.
    Fournier A; Dossus L; Mesrine S; Vilier A; Boutron-Ruault MC; Clavel-Chapelon F; Chabbert-Buffet N
    Am J Epidemiol; 2014 Sep; 180(5):508-17. PubMed ID: 25008104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
    Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
    Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort.
    Madika AL; MacDonald CJ; Fournier A; Mounier-Vehier C; Béraud G; Boutron-Ruault MC
    Menopause; 2021 Sep; 28(11):1204-1208. PubMed ID: 34581294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
    Hugon-Rodin J; Perol S; Plu-Bureau G
    Gynecol Obstet Fertil Senol; 2021 May; 49(5):455-461. PubMed ID: 33757918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of menopausal hormone therapy on the risk of ovarian cancer: Health Insurance Database in South Korea-based cohort study.
    Yuk JS; Kim M
    Menopause; 2023 May; 30(5):490-496. PubMed ID: 37022299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
    Int J Cancer; 2016 Nov; 139(10):2193-200. PubMed ID: 27451078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of postmenopausal hormone use and ovarian cancer risk.
    Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
    Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.